KSE - Delayed Quote KRW

Bukwang Pharmaceutical Co., Ltd. (003000.KS)

4,075.00
+45.00
+(1.12%)
At close: 3:30:30 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
160,086,870.10
160,086,870.10
125,928,240.77
190,909,364.53
182,491,221.46
Cost of Revenue
85,743,702.32
85,743,702.32
78,854,724.75
111,480,555.41
106,733,237.93
Gross Profit
74,343,167.78
74,343,167.78
47,073,516.02
79,428,809.12
75,757,983.53
Operating Expense
72,725,506.27
72,725,506.27
84,570,275.89
79,659,444.59
70,136,102.68
Operating Income
1,617,661.51
1,617,661.51
-37,496,759.87
-230,635.47
5,621,880.85
Net Non Operating Interest Income Expense
-2,070,849.44
-2,070,849.44
-727,769.48
-320,326.84
-1,143,968.91
Pretax Income
-2,969,515.21
-2,969,515.21
-39,569,385.99
-1,032,872.37
3,787,330.76
Tax Provision
489,246.62
489,246.62
-5,162,873.82
3,215,804.64
6,584,128.43
Net Income Common Stockholders
-2,641,325.69
-2,641,325.69
-31,329,660.64
-2,474,853.48
-916,621.57
Basic EPS
-39.00
--
-458.00
-36.00
-13.00
Diluted EPS
-39.00
--
-458.00
-36.00
-13.00
Basic Average Shares
67,726.30
--
68,405.37
68,745.93
70,509.35
Diluted Average Shares
67,726.30
--
68,405.37
68,745.93
70,509.35
Total Operating Income as Reported
1,617,661.42
1,617,661.42
-37,496,760
-230,635.59
5,621,880.94
Rent Expense Supplemental
253,959.10
253,959.10
173,725.79
60,027.43
41,178.72
Total Expenses
158,469,208.59
158,469,208.59
163,425,000.64
191,140,000
176,869,340.61
Net Income from Continuing & Discontinued Operation
-2,641,325.69
-2,641,325.69
-31,329,660.64
-2,474,853.48
-916,621.57
Normalized Income
5,279,348.83
5,279,348.83
-30,657,260.43
-1,878,877.58
-1,037,041.83
Interest Income
4,418,745.65
4,418,745.65
3,079,805.30
1,439,975.61
264,344.30
Interest Expense
6,489,595.09
6,489,595.09
3,807,574.78
1,760,302.44
1,408,313.21
Net Interest Income
-2,070,849.44
-2,070,849.44
-727,769.48
-320,326.84
-1,143,968.91
EBIT
3,520,079.88
3,520,079.88
-35,761,811.21
727,430.07
5,195,643.97
EBITDA
7,626,107.47
7,626,107.47
-31,469,373.42
5,843,959.73
10,038,400.12
Reconciled Cost of Revenue
85,743,702.32
85,743,702.32
78,854,724.75
111,480,555.41
106,733,237.93
Reconciled Depreciation
4,106,027.59
4,106,027.59
4,292,437.79
5,116,529.66
4,842,756.15
Net Income from Continuing Operation Net Minority Interest
-2,641,325.69
-2,641,325.69
-31,329,660.64
-2,474,853.48
-916,621.57
Total Unusual Items Excluding Goodwill
-9,217,150.58
-9,217,150.58
-773,297.31
-822,035.72
160,560.35
Total Unusual Items
-8,301,510.50
-8,301,510.50
-773,297.31
-822,035.72
160,560.35
Normalized EBITDA
15,927,617.97
15,927,617.97
-30,696,076.11
6,665,995.45
9,877,839.77
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-2,212,116.14
-2,212,116.14
-100,897.10
-226,059.82
40,140.09
12/31/2021 - 9/29/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

007370.KQ Jin Yang Pharmaceutical Co., Ltd.
6,350.00
+1.44%
 
008490.KS Suheung Co., Ltd.
16,170.00
-0.98%
 
000020.KS Dongwha Pharm.Co.,Ltd
6,400.00
0.00%
 
005500.KS Samjin Pharmaceuticals Co., Ltd.
17,960.00
+0.67%
 
009300.KQ Sam-A Pharm. Co., Ltd
17,130.00
-0.81%
 
006280.KS GC Biopharma Corp.
124,300.00
+2.47%
 
001540.KQ Ahn-Gook Pharmaceutical Co., Ltd.
7,150.00
-0.69%
 
004310.KS Hyundai Pharmaceutical Co., Ltd.
3,420.00
-0.87%
 
003850.KS Boryung Corporation
8,480.00
-0.35%
 
003220.KS Daewon Pharmaceutical Co., Ltd.
13,860.00
+0.22%